Amgen/ US0311621009 /
8/10/2022 9:59:59 PM | Chg. +3.64 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
252.05USD | +1.47% | 123,946 Turnover: 31.06 mill. |
-Bid Size: - | -Ask Size: - | 134.85 bill.USD | 2.79% | 24.38 |
GlobeNewswire
3/23
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
GlobeNewswire
3/23
OcyonBio Client Biosimilar Solutions, Inc. Initiates Registrational Clinical Trial for Its First Bio...
GlobeNewswire
3/21
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neu...
GlobeNewswire
3/21
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
GlobeNewswire
3/17
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program...
GlobeNewswire
3/15
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
GlobeNewswire
3/14
OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico
GlobeNewswire
3/9
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
GlobeNewswire
3/7
Dr. Gerard Blobe, M.D., Ph.D., Joins Vivacitas Oncology's Solid Tumor Medical Advisory Board
GlobeNewswire
3/3
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8,...
GlobeNewswire
3/2
AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Deli...
GlobeNewswire
3/1
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Busine...